A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q)
Shinji Nakamichi(Nippon Medical School), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Hiroshi Wakui(Jikei University School of Medicine), Takehito Shukuya(Juntendo University), Nobuaki Kobayashi(Yokohama City University), Hiroshi Nokihara(Tokushima University Hospital), Hiromi Aono(Tokyo Metropolitan Police Hospital), Tsuneo Shimokawa, Yuichi Takiguchi(Sanno Medical Center), Toshihiro Misumi(Yokohama City University), Masashi Ishihara(Gifu University Hospital), Kotone Matsuyama(Nippon Medical School), Haruhiro Saito(Kanagawa Cancer Center), Takashi Kasai, Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Shinobu Hosokawa(Okayama Red Cross General Hospital), Toshiyuki Kozuki(Shikoku Cancer Center), Naoki Furuya(St. Marianna University School of Medicine), Shunichi Sugawara(Sendai Kousei Hospital), Kaoru Kubota(Nippon Medical School Hospital), Katsuhiko Naoki(Broad Institute), Hiroshi Tanaka(Hachinohe Gakuin University), Ryo Morita(Akita Industrial Technology Center)
Cited by 6
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k